Threat of emerging virus can be stopped

Interim results of first clinical trial of Themis Bioscience’s vaccine candidate against Chikungunya fever prove successful

16-Jun-2014 - Austria

 A prophylactic vaccine candidate against Chikungunya fever, developed by Themis Bioscience GmbH induces a significant neutralizing immune response and was also confirmed as safe. These are the major interim results of a phase 1 clinical study of the company's Chikungunya vaccine candidate that uses a standard anti-measles vaccine as a vector. The Chikungunya epidemic, currently raging through the Caribbean, illustrates the urgent necessity to develop an effective vaccine against the rapid spread of the disease in tropical regions, now also threatening the North American continent.

Themis Bioscience GmbH received the interim results of a phase 1 clinical study of its Chikungunya fever prophylactic vaccine. The study was carried out on 42 subjects in the Department of Clinical Pharmacology at the Vienna General Hospital (Allgemeines Krankenhaus der Stadt Wien, ‘AKH’) and confirms the expectations pinned on the vaccine: it not only proved to be well tolerated and safe, but also exhibited the required immune response in the form of neutralizing antibodies. Even the lowest doses used showed to be effective, and increasing doses led to respective stronger immune responses in the study subjects.

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance